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Introduction 
 
Epidemiological studies have suggested the influence of host 
factors in both survival and the recurrence of breast cancer, including 
psychological factors such as depression and chronic stress [1,2]. The 
effects are mediated through hormonal and inflammatory pathways 
and have been found to influence breast cancer progression, 
angiogenesis and metastasis [3]. Recent studies have showed the 
importance of the sympathetic nervous system and neuroendocrine 
regulation in breast cancer [4-6].  More specifically, beta-adrenergic 
receptor signaling has been identified to regulate cellular processes 
involved in cancer initiation, progression and metastasis [3,4,7]. As a 
result, research interest has focused on the positive impact that beta 
adrenergic-receptor antagonist drugs may have on cancer growth and 
metastasis [8-10]. 
 Breast cancer is a complex disease with great heterogeneity and is 
one of the most common malignancies present in women, the 
complexity it presents arises from its different biological features and 
its diverse clinical outcomes [11]. Clinical parameters such as tumor 
grade and age, along with biomarkers currently available such as 
estrogen receptor (ER) and progesterone receptor (PR) status, do not 
provide the information to fully understand and describe the 
complexity of cancer [12]. This has led to the understanding that 
cancer has to be interrogated as a greater system of different disease 
types, giving rise to the need to identify new markers that will provide 
the ability to further categorize the different subtypes of the disease. 
Identification and validation of new molecular targets will allow for 
new potential therapies. 
 
 
 
 
 
 
 
 
 
  
Identification and validation of biomarkers has proven essential in 
disease diagnosis, disease stage determination and personal treatment 
guidance [11]. Understanding the pathways involved in complex 
disease states, such as cancer, has proven significant in the 
identification of effective treatment and detection methods. 
Diagnostic biomarkers have resulted in great advances, such as 
targeting specific molecules to inhibit tumor growth, but have also 
highlighted limitations, since complex disease states such as cancer 
emerge as a result of interactions of multiple molecules and different 
molecular pathways.  
Identification of groups of markers and an understanding of their 
interactions allows for greater understanding of disease pathways and 
the biological functions of associated genes. This complex collection 
of information is described by the word “interactome”, which was 
first defined in 1999 by Sanchez et al., and describes the complete 
group of interactions that are encoded by the genome of a specific 
organism, biological state or disease [13]. Understanding the 
interactome of cancer will allow the development of novel approaches 
to tackle its occurrence, progression and metastasis. Defining the 
interactome of an organism, biological state or disease, is a complex 
task and presents limitations to the approaches that can be used to 
analyze the genome and the interactions occurring within it [14,15]. 
Thus it is necessary to assess a specific question and investigate the 
interactome in the concept of that question. This is an approach 
introduced by Lancashire et al., and has been used successfully to 
screen genes in the content of a specific question, introducing less 
complexity to the approach  [15]. 
Gene expression microarrays allow for the detection of the 
presence and abundance of the mRNA hybridized to DNA on the 
array surface which ultimately provides information about the 
genomic profile of an organism [14]. Expression arrays are a high 
throughput analytical tool which allows statistical analysis of the 
genomic profile of an individual or a patient [16,17]. Such an analysis 
allows identification of specific patterns present within the patient 
profiles associated with disease status and disease characteristics [18]. 
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This information has proven vital for the identification of new 
treatments and for further understanding of disease pathways [19]. 
Over recent years, data analysis has presented significant 
challenges, due to the huge amount of data generated. Technologies 
such as microarrays present great tools for the genomic era, but the 
large amount of information generated and their multidimensional 
nature introduce limitations for data analysis [20]. The volume of 
medical data available and the growing need for personalized medicine 
and diagnosis have introduced ANNs into biomedicine with various 
applications in different disciplines and fields. ANNs are a form of 
artificial intelligence which has been shown to be capable of modeling 
complex data with high predictive accuracy [21].  Other advantages 
are that ANNs have the ability to tolerate noisy data and they are also 
capable of generalisation. Their importance is highlighted through 
their pattern recognition capabilities and due to their ability to 
generate reproducible and robust information.  
 
Experimental Procedure 
 
A systems biology approach was followed to interrogate the 
adrenergic receptor system using a collection of experimental array 
data and ANNs as an analytical tool. The ANN approach is used to 
analyze a large cohort of non-linear data using a gene of interest as an 
input to produce a list of genes in ranking order of best prediction as 
an output. Transcription profiling of human breast cancer samples 
were used and trends in gene expressions were studied using the 
adrenergic gene as an input.  
The EMBL-EBI database library (www.ebi.ac.uk/arrayexpress) 
was used to identify a suitable dataset for our analysis. The data set 
chosen was labeled as E-GEOD-4922. The dataset consisted of 
transcription profiling of 578 human breast cancer samples, from 
Uppsala and Singapore cohorts. The dataset samples were obtained 
from both A-AFFY-33 (Affymetrix GeneChip Human Genome HG-
U133A) and A-AFFY-34 (Affymetrix GeneChip Human Genome 
HG-U133B) platforms. Clinical and pathological characteristics of 
the patient samples are presented in table 1. The dataset is comprized 
of 578 samples of which 422 were ER+ (estrogen receptor positive) 
and 156 samples which were negative, unknown or blank of 
information. This study focuses on the ER+ cases due the significant 
sample size. A dataset equally as big for ER- (estrogen receptor 
negative) was not identified thus a comparable study was not possible. 
Samples that were characterized as negative, unknown or blank of 
information for estrogen receptor status, were excluded from the 
analysis. This led to a total of 422 samples that were further 
processed to compile the information of each patient within one file. 
The final file contained 211 patient profiles, including both 
information from A-AFFY-33 (22,283 genes) and A-AFFY-34 
(22,645 genes). Each patient profile is associated with 44,928 gene 
probes. 
The microarray data was analyzed using the ANN stepwise 
method, which incorporates a three-layer feed-forward multi-layer 
perceptron (MLP) with a back propagation (BP) algorithm and a 
sigmoidal transfer function. Learning rate and momentum were set to 
0.1 and 0.5 respectively. The algorithm incorporates two hidden 
nodes (to maintain a parsimonious solution) in the hidden layer and 
utilizes a Monte Carlo cross-validation (MCCV) and a bootstrapping 
approach, which is used to provide an unbiased estimation of the 
error rate. MCCV randomly assigns training, validation and test sets 
which in this case include 60%, 20% and 20% respectively 
[20,22,23]. All three groups are assigned the cases randomly. 
Bootstrapping is used due to its reliability for generalisation of the 
network. The training subset includes 127 patient profiles (60%), the 
test subset includes 42 patient profiles (20%) and the validation 
subset also includes 42 patient profiles (20%). The test subset allows 
the model to be independently tested on a blind data set and the 
validation subset assesses the model performance during the training 
process [14,24].  
 
 
Each stepwise analysis generated 5 files, one for each loop it was 
set to run. A file was then created containing the averaged 
information, which was arranged in order of ascending average test 
error. The input probes were examined using the median training 
performance (percentage of correctly classified cases) and their average 
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test Root Mean Squared (RMS) error. The top 100 probes were 
selected from the list (RMS error <0.12, Figure 2) resulting in the 
most important genes being utilized for further study. 
After analysing the first round of data it was concluded that the 
analysis would focus on building a map with beta-2-adrenergic 
receptor as the initial starting point. A non-reductionist network 
growth approach was used as an analysis strategy. ADRB2 was used to 
create a network of important genes and to study links between them. 
All the data was generated and the results were studied and analyzed 
conducting network inference. A simplistic network was created for 
the input probe and the top 10 interconnections were identified for 
the first set of data and presented in that network. The results were 
studied in general to identify commonalities between the probe sets 
and also to identify patterns within the data. 
 
 
 
 
 
 
 
 
 
 
Results 
 
The probe corresponding to ADRB2 was identified and used as 
the input for the analysis. The top 100 ranking probes were studied 
and the top 10 ranking genes were analyzed further due to their good 
performance (based on their low predictive error value). Figure 2 
explains the selection process and the reason the top 100 probes were 
used as the cut off value.  
ADRB2 was the initial input gene of the analysis and the top 10 
ranking genes were further analyzed to identify patterns within the 
data and common gene signatures. As seen in table 2, the first ranking 
probe corresponds to the ADRB2 gene, this allows for validation of 
the technique, since it informs us that the probe is the most predictive 
for itself. The genes following are the top 10 most predictive genes 
for ADRB2 gene expression. The genes identified are listed in table 2 
and their gene names are listed in table 3. 
A simplistic network has been constructed which presents the 
exact number of interconnections occurring in the further analysis of 
the top 10 genes. The interconnections can be seen both in table 2 
and figure 3 which presents the analysis technique along with the 
interesting aspect of our results since there are multiple connections 
occurring between the genes identified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Artificial Neural Network design used for the specific project. 
Inputs (ix) are fed into the algorithm and adjusted with a corresponding 
weight (wx), and then summed and processed using a sigmoidal function, 
and a bias input. Output is adjusted to weights (wHX), summed and fitted 
to the sigmoidal function. Through each step the back propagation 
algorithm is used to adjust the weights and improve the performance. 
 
Figure 2. (A) Predictive error distribution of the genes for unseen data. 
The dashed line indicates the position of the 100th gene. The blue line is 
included to identify the increase of the predictive error value. (B) 
Predictive error distribution of the top 100 genes for unseen data. Blue 
line is included to indicate the increase of the predictive error value.  (A, B) 
Graph B is a zoomed section of A, to show the reason the cut-off value 
was selected at the top 100 probes. The blue line in both graphs is set at 
0.12 which shows the increase of the predictive error after the top 100 
probes. Error bars are not included in both graphs for clarity. 
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By studying the top 100 probes for each of the top 11 genes 
analyzed it was possible to identify common genes and patterns 
occurring within the data. Table 4 presents the most common gene 
signatures. Genes from table 4 were selected for further analysis and 
the results were compared with the data obtained from the analysis of 
ADRB2 and its top 10 genes. The large amount of data generated 
from the analysis of all the genes selected did not allow for an 
extensive analysis, but gave the opportunity to validate the results 
obtained from the previous runs.  The data was studied and most 
genes found from the analysis of ADRB2 and the top 10 genes were 
found to reoccur. Tables 5 and 6 present important immunologically 
related genes and important cancer related genes which were 
identified. 
 
 
 
 
 
 
 
 
Discussion 
 
Several of the markers identified have been found to be of 
importance and relevance to breast cancer. Our aim was to study a 
cohort of breast cancer gene expression microarrays in the concept of 
the adrenergic receptor gene. The gene signatures found are the most 
predictive and of greatest relevance to the beta-2-adrenergic receptor 
and have been identified through an analysis of breast cancer samples. 
This provides information about the expression of genes both related 
to the adrenergic receptor as well as breast cancer. 
 
Chemokines are chemotactic cytokines with the ability to bind to 
GPCRs [25]. Chemokines were initially identified as small molecules 
that function as activation and recruitment molecules for leukocytes 
such as neutrophils and monocytes; they were originally considered as 
mediators of inflammatory pathways [26,27]. Chemokines and their 
receptors have since been discovered to have an essential role in tumor 
initiation, promotion and progression. 
Lazennec et al., [26] published a review on chemokines and 
chemokine receptors and their involvement in cancer. They report the 
Figure 3. ADRB2 network created presenting the top 10 genes resulting 
from its analysis and interconnections occurring in second layer analysis. 
Connections are color coded and correspond to the equivalent colored 
gene. Connections with the same color have originated from the analysis 
of the common equivalently colored gene. 
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importance of the tumor microenvironment and that chemokines are 
produced by tumor cells and by cells of the tumor microenvironment 
such as cancer-associated fibroblasts, mesenchymal stem cells, 
endothelial cells, tumor-associated macrophages and tumor-associated 
neutrophils. The review concentrates on tumor metastasis, focusing 
on the concentration of chemokines produced at sites of metastasis, 
which attracts the cancer cells and causes them to metastasise [26]. 
This is one of the reasons that explain the preferential pattern 
occurring in metastatic sites arising from different types of cancer. 
The importance of CXCL12, DARC, CCL21, and CCL5 is 
highlighted, which are also gene signatures arising in our analysis. The 
review reports their importance in tumor metastasis and the tumor 
microenvironment and offers various examples in the literature were 
they have been found to be associated with breast cancer. 
 
 
 
The beta-2-adrenergic receptor has been identified to regulate 
several cellular pathways and has also been found to have an 
important role in initiation and progression of cancer [1,6,28,29]. It 
has been described to contribute to pathways of inflammation, 
angiogenesis, epithelial mesenchymal transition and apoptosis [4]. 
Within the tumor microenvironment and cancer pathways tumor 
associated macrophages have been identified to be related to the beta-
adrenergic signalling pathways [4]. Powe et al., [9] showed that cell 
migration is mediated by beta-adrenergic receptors and that beta-
blockers inhibited the process, specifically the antagonist propranolol. 
Sloan et al., [30] published their results on the effect of stress on 
metastasis development. They report that the sympathetic nervous 
system induces a metastatic switch in primary breast cancer and 
emphasize the activation of the sympathetic nervous system as a target 
for regulation of breast cancer metastasis. Both Powe et al. [9] and 
Sloan et al. [30] report the evidence and form the hypothesis of 
utilising the beta-adrenergic receptor for novel antimetastatic therapies 
that will increase survival and induce prometastatic gene expression in 
primary breast cancers. Cole et al., [4] report several pathways that 
have been identified to be involved both with beta-2-adrenergic 
receptor and cancer, specifically cellular and molecular processes that 
mediate beta-adrenergic receptor and its influence on tumor 
progression. Pathways that are mediated by the beta-adrenergic 
receptor include recruitment of macrophages into the tumor, increase 
in cytokine expression, angiogenesis, matrix metalloproteinase 
concentration increase in invasion, tumor cell mobilisation and 
motility, focal adhesion kinase mediated resistance to apoptosis, and 
BAD-mediated resistance to apoptosis [4]. All these pathways are of 
great importance in cancer and their association needs to be further 
investigated to conclude on the hypothesis the adrenergic receptor has 
an important role in breast cancer. 
This study’s findings, along with the studies mentioned above 
reveal commonalities in gene signatures that have been stated to be 
related to both beta-adrenergic receptor and cancer. Gene signatures 
such as IL6, MMP9, MMP1, IFNGR1, CXCL12, FOSB, LCK, 
CCL21, DARC, ERG, MYH11,RHOJ, IGF1, ETS1 which have 
been identified in our research are present both in cancer pathways 
and beta-adrenergic pathways. It is possible to identify commonalities 
and also to find the genes identified in our analysis that play an 
important role in these pathways. This provides validation for the 
technique used and also gives information about the relationships 
between gene expression levels of cancer related genes and the 
adrenergic receptor. This knowledge could be used in the design of 
novel therapeutic strategies involving combination therapy to target 
upstream and downstream molecules in adrenergic receptor-mediated 
disease. 
 
 
 
Conclusions 
 
This study provides an insight into the relationship between the 
beta-2-adrenergic receptor and breast cancer disease pathways. Gene 
signatures were identified and patterns within the results were found 
that correlate with the information currently available in the literature. 
This allows the understanding of the common pathways between the 
adrenergic receptor and breast cancer and provides markers which 
support the studies suggesting beta-blockers could be incorporated in 
designing new breast cancer treatment strategies. The results are 
promising and will be further validated to obtain greater 
understanding of the mechanisms they are involved in.   
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Future Work  
 
The analysis conducted has generated a large amount of data that 
needs to be further analyzed to investigate all the possible patterns 
and gene interaction that could arise. Further analysis would provide 
information on key pathways and possible gene associations.  
The current project analyzed a single dataset, which included 211 
patient samples run on two affymetrix platforms and only ER+ 
patients samples were included. It would be possible to expand the 
possibilities and design the experiment differently in order to obtain 
more information about various other situations. Analysis of multiple 
datasets would allow for comparison of the results and identification 
of common patterns. It would also be possible to find datasets that 
include an ER- cohort, or healthy donors. This would allow 
comparison of the results to identify different patterns occurring in 
different breast cancer subtypes. 
Combination of other analytical techniques could also be used 
thus providing more confidence in the information obtained. Both in 
silico and in vitro techniques could be investigated and a different 
experimental approach could be designed in order to investigate the 
same cohort and compare the results. The investigation of the 
immunohistochemical protein expression of certain markers identified 
would allow for validation of the results obtained and would provide 
information on whether they can be used as biomarkers for breast 
cancer patient sample classification.  
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